{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PegIFN%2FRBV&page=2", "query": { "intervention": "PegIFN/RBV", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PegIFN%2FRBV&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T15:20:11.494Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01297270", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 658, "start_date": "2011-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-09-18", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297270" }, { "nct_id": "NCT01265511", "title": "Study of SCY-635, Pegasys and Copegus in Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Infection" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SCY-635", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Copegus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2010-11", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 3, "location_summary": "San Francisco, California • Durham, North Carolina • San Antonio, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265511" }, { "nct_id": "NCT00135798", "title": "Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "LADR Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2005-09", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2013-04-23", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135798" }, { "nct_id": "NCT01314261", "title": "Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C", "Hepatitis C Virus (HCV) Infection" ], "interventions": [ { "name": "ABT-267", "type": "DRUG" }, { "name": "Pegylated interferon (pegIFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "Placebo for ABT-267", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2011-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01314261" }, { "nct_id": "NCT01074008", "title": "A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Peginterferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 74, "start_date": "2010-03", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074008" }, { "nct_id": "NCT00774397", "title": "Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 201335 NA 240 mg QD / LI", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI 201335 NA 120mg QD / LI", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg QD", "type": "DRUG" }, { "name": "BI 201335 NA 240 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 719, "start_date": "2008-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-11-16", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 10, "location_summary": "San Francisco, California • Chicago, Illinois • Lutherville, Maryland + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774397" }, { "nct_id": "NCT00056862", "title": "Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2003-03", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-12-06", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056862" }, { "nct_id": "NCT01289782", "title": "An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TMC435", "type": "DRUG" }, { "name": "Peginterferon alpha-2a (PegIFN alpha-2a)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 395, "start_date": "2011-02", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 22, "location_summary": "Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289782" }, { "nct_id": "NCT01330316", "title": "A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 119, "start_date": "2011-07", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 20, "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330316" }, { "nct_id": "NCT02966795", "title": "A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus (HCV)" ], "interventions": [ { "name": "Glecaprevir/Pibrentasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2017-01-25", "completion_date": "2018-08-29", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-09-27T15:20:11.494Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • West Hollywood, California + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02966795" } ] }